Latest News on OABI

Financial News Based On Company


Advertisement
Advertisement

Weekly Recap: Revenue guidance raised and batoclimab approved in China

https://www.tradingview.com/news/tradingview:21643b508fdd2:0-weekly-recap-revenue-guidance-raised-and-batoclimab-approved-in-china/
OmniAb, Inc. (NASDAQ:OABI) increased its 2026 revenue guidance after its Q3 revenue exceeded estimates and its net loss decreased. Additionally, Harbour BioMed's batoclimab, developed using OmniAb’s platform, received approval in China for a form of myasthenia gravis. The royalty impact from this approval is currently uncertain.

OmniAb, Inc. (NASDAQ:OABI) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oabi/omniab/news/omniab-inc-nasdaqoabi-just-reported-third-quarter-earnings-a
OmniAb, Inc. (NASDAQ:OABI) reported better-than-expected third-quarter revenues of US$4.0m, surpassing forecasts by 14%, although the company still recorded a loss of US$0.12 per share, which was marginally smaller than anticipated. Following these results, analysts have modestly increased their revenue and loss per share predictions for 2027, now forecasting US$47.0m in revenue and a narrowed loss of US$0.26 per share. Despite these upgrades, the consensus price target remains unchanged at US$8.33, suggesting analysts don't foresee a significant long-term impact from the latest estimates.

OmniAb Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/10/62759824/omniab-q3-2026-earnings-call-transcript
OmniAb reported strong third-quarter 2026 financial results, with revenue increasing to $4 million, driven by service and exploration revenue. The company secured a major licensing deal with Eli Lilly for an ion channel program and raised its full-year 2026 revenue guidance to $35-$39 million, projecting break-even cash flow. OmniAb's Exploration platform, an AI-powered B cell screening tool, is expected to generate significant recurring revenue, and their active programs and partnerships continue to grow, including a recent drug approval in China for batoclimab.

Press Release: OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights

https://www.moomoo.com/news/post/1003005870/press-release-omniab-reports-third-quarter-2026-financial-results-and
This press release details OmniAb's financial results and business highlights for the third quarter of 2026. The report covers key financial metrics and significant operational achievements during that period.

OmniAb Raises 2026 Revenue Outlook After Third-Quarter Revenue Grows to $4.0 Million

https://www.tradingview.com/news/tradingview:b58981bd663f1:0-omniab-raises-2026-revenue-outlook-after-third-quarter-revenue-grows-to-4-0-million/
OmniAb (OABI) reported a significant increase in third-quarter 2026 revenue, reaching $4.0 million, up from $2.2 million a year prior, while its net loss was $15.7 million. For the first nine months, revenue climbed to $31.8 million, driven by milestone revenue, and the net loss narrowed to $29.3 million. Following these results, the company raised its full-year 2026 revenue guidance to $35 million–$39 million and adjusted its year-end cash and cash equivalents forecast to $53 million–$57 million.
Advertisement

OmniAb Inc. (NASDAQ:OABI) Q3 2026 Revenue Beat and Raised Guidance Offset by Sell-the-News Pressure

https://www.chartmill.com/news/OABI/Chartmill-57378-OmniAb-Inc-NASDAQOABI-Q3-2026-Revenue-Beat-and-Raised-Guidance-Offset-by-Sell-the-News-Pressure
OmniAb Inc. (NASDAQ:OABI) reported Q3 2026 revenue of $3.99 million, exceeding the $3.56 million consensus, and a slightly narrower loss per share of $0.12. The company also raised its full-year 2026 revenue guidance to $35 million-$39 million. Despite these positive results, the stock experienced premarket pressure, dropping about 15.3%, as investors focused on the quality of the revenue beat and a prior rally, indicating a "sell-the-news" reaction.

OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights

https://www.biospace.com/press-releases/omniab-reports-third-quarter-2026-financial-results-and-business-highlights
OmniAb, Inc. reported strong third-quarter 2026 financial results, with revenue increasing to $4.0 million from $2.2 million in the prior-year period. The company also raised its full-year 2026 revenue and cash outlook, expecting revenue between $35 million and $39 million. Key business highlights included new collaborations, the expanded commercial launch of its xPloration platform, and the introduction of OmniTides.

Earnings Preview: OmniAb to Report Financial Results Pre-market on October 30

https://www.moomoo.com/news/post/1002410223/earnings-preview-omniab-to-report-financial-results-pre-market-on
OmniAb is scheduled to report its financial results pre-market on October 30. Investors will be looking for insights into the company's performance, particularly regarding its revenue and profitability. The report is expected to provide key details on the company's operational achievements and future outlook.

OmniAb to Participate in Upcoming Investor Conferences in November 2026

https://www.biospace.com/press-releases/omniab-to-participate-in-upcoming-investor-conferences-in-november-2026
OmniAb, Inc. (NASDAQ: OABI) announced its management will participate in several investor conferences in November 2026, including the Stifel Healthcare Conference, Truist Securities BioPharma Symposium, Jefferies London Healthcare Conference, and Craig-Hallum Investor Conference. These events will provide opportunities for one-on-one meetings with investors to discuss OmniAb's cutting-edge discovery research technology for next-generation therapeutics. The company specializes in licensing technology for identifying optimal antibodies and target-binding proteins through its Biological Intelligence™ platform and xPloration AI-powered screening.

OmniAb, Inc. Estimates – NASDAQ:OABIW

https://www.tradingview.com/symbols/NASDAQ-OABIW/financials-estimates/
This article provides an overview of OmniAb, Inc. (NASDAQ: OABIW) financial estimates and data available on TradingView. It directs users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform allows comparison of actual results with average, high, and low estimates, and visualization of trends over time.
Advertisement

OmniAb, Inc. Estimates – NASDAQ:OABI

https://www.tradingview.com/symbols/NASDAQ-OABI/financials-estimates/
This article provides an overview of OmniAb, Inc. (NASDAQ: OABI) financial estimates available on TradingView. It directs users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform allows comparison of actual results with average, high, and low estimates, and visualization of trends.

OmniAb to Report Third Quarter 2026 Financial Results on October 30

https://finance.yahoo.com/healthcare/articles/omniab-report-third-quarter-2026-200500590.html
OmniAb, Inc. (NASDAQ: OABI) announced it will report its financial results for the third quarter and nine months ended September 30, 2026, before the U.S. financial markets open on Friday, October 30, 2026. The company will also host a conference call and webcast on the same day at 8:00 a.m. Eastern time to discuss the results and provide business updates. OmniAb specializes in providing discovery research technology to pharmaceutical and biotech companies for the development of next-generation therapeutics.

Press Release: OmniAb to Report Third Quarter 2026 Financial Results on October 30

https://www.moomoo.com/news/post/1001211115/press-release-omniab-to-report-third-quarter-2026-financial-results
OmniAb announced it will report its third quarter 2026 financial results on October 30, 2026. The company will issue a press release after market close, followed by a conference call and webcast at 4:30 p.m. ET to discuss the results.

OmniAb Leads The Pack Of 3 Intriguing Penny Stocks

https://simplywall.st/stocks/us/media/nasdaq-tbla/taboolacom/news/omniab-leads-the-pack-of-3-intriguing-penny-stocks
This article highlights three penny stocks with intriguing financial characteristics: OmniAb (OABI), Taboola.com (TBLA), and SES AI (SES). OmniAb, a biotechnology company, shows strong revenue growth and strategic partnerships despite unprofitability. Taboola.com, an AI-based advertising platform, faces legal challenges but has a stable financial footing and significant earnings surge. SES AI, focused on battery technology, is expanding production but remains unprofitable and faces potential delisting despite a stable balance sheet.

OmniAb to Report Third Quarter 2026 Financial Results on October 30

https://www.streetinsider.com/Business+Wire/OmniAb+to+Report+Third+Quarter+2026+Financial+Results+on+October+30/27187111.html
OmniAb, Inc. (NASDAQ: OABI) announced it will report its financial results for the three and nine months ended September 30, 2026, before the U.S. financial markets open on Friday, October 30, 2026. The company will also host a conference call on the same day at 8:00 a.m. Eastern time to discuss the third quarter results and provide business updates. OmniAb specializes in providing cutting-edge discovery research technology to pharmaceutical and biotech companies for developing next-generation therapeutics.
Advertisement

OmniAb Q3FY26 Results: Earnings call set for October 30

https://scanx.trade/stock-market-news/companies/omniab-q3fy26-results-earnings-call-set-october-30/53554396
OmniAb, Inc. will report its financial results for Q3FY26 on October 30, 2026, before the U.S. financial markets open. The company will host a conference call on the same day at 8:00 a.m. Eastern time to discuss the results and provide business updates. OmniAb specializes in licensing discovery research technology, utilizing engineered transgenic animals and AI-powered screening to identify antibodies and target-binding proteins for drug development, operating on a business model that includes upfront fees, milestones, and royalties.

OmniAb to Report Third Quarter 2026 Financial Results on October 30

https://www.financialcontent.com/article/bizwire-2026-10-14-omniab-to-report-third-quarter-2026-financial-results-on-october-30
OmniAb, Inc. (NASDAQ: OABI) announced it will report financial results for the three and nine months ended September 30, 2026, before the U.S. financial markets open on Friday, October 30, 2026. The company will also host a conference call and webcast on the same day at 8:00 a.m. Eastern time to discuss these results and provide business updates. The call details, including phone numbers and webcast link, are provided for interested parties.

OmniAb Leads The Pack Of 3 Intriguing Penny Stocks

https://simplywall.st/stocks/us/media/nasdaq-tbla/taboolacom/news/omniab-leads-the-pack-of-3-intriguing-penny-stocks/amp
This article identifies three intriguing penny stocks with strong financial health and long-term potential: OmniAb (OABI), Taboola.com (TBLA), and SES AI (SES). OmniAb, a biotechnology company, shows increased revenue and strategic partnerships despite being unprofitable, while Taboola.com, an AI-based advertising platform, faces legal challenges but has strong cash reserves. SES AI, focused on battery technologies, is expanding production but also remains unprofitable with a potential delisting risk.

StoneX raises OmniAb stock price target to $6 on new products

https://www.investing.com/news/analyst-ratings/stonex-raises-omniab-stock-price-target-to-6-on-new-products-93CH-4936878
StoneX has increased its price target for OmniAb Inc. (NASDAQ:OABI) shares to $6.00 from $4.00, reiterating a Buy rating. This adjustment follows OmniAb's Investor and Analyst Day, where the company launched a new product line, OmniTides, and expanded its xPloration Platform, alongside reiterating its 2026 financial guidance. The stock has seen a significant 164% gain over the last year despite a recent 12% dip, and analysts maintain a Strong Buy consensus.

OABI Maintained by Leerink Partners -- Price Target Raised to $1

https://www.gurufocus.com/news/9113843/oabi-maintained-by-leerink-partners-price-target-raised-to-1200
Leerink Partners has reaffirmed its "Outperform" rating for OmniAb (OABI) and raised its price target from $10.00 to $12.00, reflecting optimism about the company's future performance. Despite this positive analyst view, GuruFocus indicates OABI is significantly overvalued at $4.64 against a GF Value™ of $2.77, and the company currently shows low profitability. Investors are advised to proceed with caution due to the high valuation and mixed signals from institutional investors, even with strong financial strength and growth potential.
Advertisement

OABI: xPloration scales commercialization as new platforms and royalties mature

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4229345:0-oabi-xploration-scales-commercialization-as-new-platforms-and-royalties-mature/
OABI has expanded the availability of its xPloration platform and introduced the OmniTides peptide platform to enhance commercialization and partnering prospects. The company maintains its FY2026 revenue guidance of $32M–$36M and cash operating expenses of $51M–$55M, anticipating near breakeven cash flow. This information is based on the OmniAb, Inc. Investor and Analyst Day 2026 Audio Transcript from October 6, 2026.

OmniAb Investor Day Spotlights Royalty Pipeline, OmniTides Launch and xPloration Growth

https://finance.yahoo.com/healthcare/articles/omniab-investor-day-spotlights-royalty-170232806.html
OmniAb's Investor Day highlighted its growing royalty pipeline with over 110 partners and 125 programs, projecting significant future milestones and royalties. The company introduced OmniTides for peptide discovery and expanded the xPloration B-cell screening platform, expecting substantial revenue growth from both. Management reaffirmed 2026 revenue guidance of $32 million–$36 million and expects to approach cash-flow breakeven, indicating a strong outlook for its technology platforms.

Leerink Partners maintains Outperform rating on OmniAb, $12 price target

https://www.tradingview.com/news/tradingview:7434623378ffc:0-leerink-partners-maintains-outperform-rating-on-omniab-12-price-target/
Leerink Partners has maintained its Outperform rating on OmniAb (OABI) with a $12 price target, indicating a significant upside from its current stock price. The positive outlook is driven by OmniAb's AI-driven drug discovery platform, xPloration, which is expected to capture a substantial share of the growing lab-in-the-loop market. Additionally, the company's robust royalty portfolio, featuring 425 active programs, is anticipated to generate considerable milestone revenues and royalties, supporting scalable growth without extensive additional financing.

Stifel reiterates OmniAb stock rating on technology platform By Investing.com

https://ng.investing.com/news/stock-market-news/stifel-reiterates-omniab-stock-rating-on-technology-platform-93CH-2725587
Stifel reiterated a Buy rating and a $9.00 price target on OmniAb, Inc. (NASDAQ: OABI) following an investor event where the company unveiled new peptide discovery technology (OmniTides) and elaborated on its xPloration platform and commercial launch plans. Despite a recent stock pullback, OmniAb has seen significant growth over the past six months, and analysts maintain a Strong Buy consensus. The firm highlighted upcoming data catalysts and the breadth of OmniAb's late-stage pipeline, emphasizing its differentiated technology offerings as a competitive advantage.

StoneX raises OmniAb stock price target to $6 on new products

https://ng.investing.com/news/stock-market-news/stonex-raises-omniab-stock-price-target-to-6-on-new-products-93CH-2725753
StoneX has increased its price target for OmniAb (NASDAQ:OABI) shares to $6.00 from $4.00, reiterating a Buy rating, following the company's Investor and Analyst Day. OmniAb announced new product launches, including OmniTides for peptide development, and expanded its xPloration Platform, leading to the analyst's revised target. This comes after OmniAb's strong Q2 2026 results and a reiterated financial guidance for 2026.
Advertisement

StoneX maintains Buy rating on OmniAb, $6 price target

https://www.tradingview.com/news/tradingview:92118a83a1ae0:0-stonex-maintains-buy-rating-on-omniab-6-price-target/
StoneX has reiterated its Buy rating for OmniAb (OABI) and set a price target of $6.00, suggesting a 37.9% upside from its recent closing price. This positive outlook is driven by OmniAb's strong R&D catalysts, robust financial results, and diverse therapeutic platforms like OmniRat and OmniChicken, which position the company well within the biopharmaceutical industry.

StoneX raises OmniAb stock price target to $6 on new products

https://ca.investing.com/news/stock-market-news/stonex-raises-omniab-stock-price-target-to-6-on-new-products-93CH-4869987
StoneX has increased its price target for OmniAb (NASDAQ:OABI) to $6.00 from $4.00, maintaining a Buy rating, following the company's first Investor and Analyst Day. This adjustment is attributed to OmniAb's launch of OmniTides, a new product for peptide development, and the expanded availability of its xPloration Platform. The company also reiterated its 2026 financial guidance and reported strong Q2 2026 results, exceeding Wall Street expectations.

OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day

https://www.biospace.com/press-releases/omniab-highlights-partner-pipeline-xploration-plans-and-outlook-and-introduces-the-omnitides-platform-at-investor-analyst-day
OmniAb held its Investor & Analyst Day to showcase recent partner developments, the expanded availability of its xPloration® platform, and the introduction of its new OmniTides™ peptide discovery platform. The company highlighted its strong partner pipeline with significant potential milestones and royalties, anticipating primary completion of up to 19 clinical trials by its partners in 2026-2027. OmniAb expects substantial revenue growth from the xPloration platform, projecting revenue to double in both 2027 and 2028 after an estimated $2 million to $3 million in 2026.

OABI: A broad partnered pipeline and xploration expansion underpin growth plans and reaffirmed 2026 guidance

https://www.tradingview.com/news/urn:summary_document_slides:quartr.com:4228475:0-oabi-a-broad-partnered-pipeline-and-xploration-expansion-underpin-growth-plans-and-reaffirmed-2026-guidance/
OmniAb, Inc. (OABI) has reaffirmed its 2026 guidance, supported by a broad partnered pipeline of 110 active partners and 425 programs, with over $3 billion in potential contracted milestones. The company's xploration general availability is set to begin in October 2026, with revenue projected to double in both 2027 and 2028. This outlook highlights significant growth expected from its expanded portfolio and upcoming product launch.

OmniAb, Inc. (OABI) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/OABI/
This article provides a comprehensive overview of OmniAb, Inc. (OABI), including its current stock price ($4.35, down 11.59%), key financial metrics, and company profile. It highlights OmniAb's biotechnology platform, which focuses on licensing discovery research technology for therapeutic development, and details its various proprietary animal-based and AI-driven technologies for antibody discovery. The report also includes performance overviews, earnings trends, analyst insights, and valuation measures for OABI.
Advertisement

All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy

https://sg.finance.yahoo.com/news/know-omniab-inc-oabi-rating-150005991.html
OmniAb, Inc. (OABI) has received a Zacks Rank #2 (Buy) rating, driven by an upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's earnings, which often correlates with an increase in stock price due to institutional investor activity. The Zacks rating system emphasizes the power of earnings estimate revisions in predicting near-term stock movements.

OmniAb, Inc. (OABI) Analyst/Investor Day - Slideshow (NASDAQ:OABI) 2026-10-06

https://seekingalpha.com/article/4952328-omniab-inc-oabi-analyst-investor-day-slideshow
OmniAb, Inc. (OABI) released a slide deck for its Analyst/Investor Day held on October 6, 2026. This content was published by SA Transcripts, which specializes in providing earnings call transcripts and other related developments. The article emphasizes that the slide deck is in conjunction with the event.

OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day

https://finance.yahoo.com/healthcare/articles/omniab-highlights-partner-pipeline-xploration-120000542.html
OmniAb, Inc. hosted an Investor & Analyst Day to discuss its strategy, technological capabilities, and future growth. Key highlights included the company's strong partner pipeline with potential for numerous clinical trial completions, the broader commercial launch of its AI-powered xPloration® platform with revenue projections, and the introduction of OmniTides™, a new peptide discovery offering. The company aims to leverage its technologies and business model for sustainable, long-term growth in next-generation therapeutics.

OmniAb expands xPloration platform access and launches peptide discovery unit

https://www.streetinsider.com/Corporate+News/OmniAb+expands+xPloration+platform+access+and+launches+peptide+discovery+unit/27152287.html
OmniAb, Inc. held an Investor & Analyst Day where it announced the expansion of commercial access to its xPloration platform, now available for purchase by all customers. The company also introduced OmniTides, a new peptide discovery platform. OmniAb projected significant revenue growth for xPloration and highlighted its partner pipeline with numerous clinical trials expected to complete in late 2026 and 2027.

OmniAb to Host Investor & Analyst Day on October 6, 2026

https://finance.yahoo.com/healthcare/articles/omniab-host-investor-analyst-day-120000637.html
OmniAb, Inc. (NASDAQ: OABI) will host an Investor & Analyst Day on October 6, 2026, in Emeryville, CA. The event will include presentations from the executive leadership team, corporate updates, discussions on partner programs and the xPloration® platform, and technology innovations, along with lab tours for in-person attendees. Registration is available for both in-person and virtual participation.
Advertisement

OmniAb, Inc. - Common Stock (Nasdaq:OABI) Detailed Stock Data

https://markets.chroniclejournal.com/observerreporter/quote/detailedquote?Symbol=537%3A2578379956
This article provides detailed stock data for OmniAb, Inc. (Nasdaq: OABI), including its current price, daily performance, and historical price performance over various periods. It also lists key financial metrics such as open, close, bid/ask prices, 52-week high/low, and trading volume. The data indicates significant year-to-date and annual gains for the stock.

OmniAb to Host Investor & Analyst Day on October 6, 2026

https://www.biospace.com/press-releases/omniab-to-host-investor-analyst-day-on-october-6-2026
OmniAb, Inc. (NASDAQ: OABI) has announced details for its upcoming Investor & Analyst Day, scheduled for October 6, 2026, in Emeryville, CA. The event will feature presentations from the company's executive leadership, including corporate updates, discussions on partner programs, technology innovations, and a focus on its xPloration® platform. Both in-person and virtual participation are available, with in-person attendees also having the opportunity for technology demonstrations and laboratory tours.

OmniAb Inc. OABI Stock Holds Support As Traders Weigh Weak Margins

https://stockstotrade.com/news/omniabinc-oabi-news-2026_09_06/
OmniAb Inc. (OABI) stock is experiencing an 8.01% decline due to concerns over reduced biotech funding and partnership delays, despite strong gross margins and balance sheet liquidity. The company faces deeply negative profitability and a stretched valuation compared to its peers, making it a high-risk, high-upside trading vehicle rather than a value play. Traders are advised to focus on price action around support and resistance levels, with an emphasis on defining risk due to the stock's thin liquidity and volatility.

OmniAb Inc. Stock Holds Range As Traders Weigh Deep Losses Against Strong Balance Sheet

https://timothysykes.com/news/omniabinc-oabi-news-2026_09_05/
OmniAb Inc. (OABI) stock is trading in a tight range despite significant operating losses, driven by a recent clinical trial setback. While the company exhibits strong liquidity and a low debt-to-equity ratio, its valuation is stretched given shrinking revenue and lack of clear profitability. Traders are watching key technical support and resistance levels, with an emphasis on risk management due to potential for rapid price swings.

OmniAb to Participate in Upcoming Investor Conferences

https://finance.yahoo.com/healthcare/articles/omniab-participate-upcoming-investor-conferences-120000500.html
OmniAb, Inc. announced its management will participate in two upcoming investor conferences: the Nasdaq/LD Micro Summit Series on September 9, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. Management plans to provide a corporate overview and hold one-on-one meetings with investors at both events. OmniAb is a biotechnology company specializing in discovery research technology for next-generation therapeutics.
Advertisement

OmniAb (NASDAQ:OABI) Passes Minervini Trend Template and High-Growth Momentum Screen

https://www.chartmill.com/news/OABI/Chartmill-53880-OmniAb-NASDAQOABI-Passes-Minervini-Trend-Template-and-High-Growth-Momentum-Screen
OmniAb (NASDAQ:OABI) has passed both the Minervini Trend Template and a high-growth momentum screen, indicating strong technical and accelerating fundamental performance. The drug discovery company shows positive short-term and long-term trends, with significant EPS and revenue growth in recent quarters. Despite a high technical rating, the setup rating is low due to recent volatility, and the company still faces fundamental risks including negative free cash flow and uneven revenue on a trailing basis.

Why Is Omniab Stock Rallying After Eli Lilly Deal?

https://www.tradingview.com/news/benzinga:05c4f6dbb094b:0-why-is-omniab-stock-rallying-after-eli-lilly-deal/
OmniAb, Inc. (NASDAQ: OABI) shares surged after the company announced a global collaboration and license agreement with Eli Lilly and Company (NYSE: LLY) for an ion channel program. The deal includes an upfront payment and up to $370 million in potential milestone payments, along with tiered royalties. OmniAb also raised its 2026 cash outlook due to recent licensing activity, now expecting $49 million to $53 million in cash and cash equivalents.

OmniAb partners with Eli Lilly on ion channel program

https://www.investing.com/news/company-news/omniab-partners-with-eli-lilly-on-ion-channel-program-93CH-4862482
OmniAb, Inc. has announced a global collaboration and license agreement with Eli Lilly and Company for an ion channel drug discovery program. Under the agreement, OmniAb will receive an upfront payment and is eligible for up to $370 million in milestone payments, plus tiered royalties on global net sales. The collaboration will leverage OmniAb's technology platform and expertise in ion channel discovery and screening for therapeutic development.

OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook

https://www.tradingview.com/news/gurufocus:f7b28bd1e094b:0-omniab-jumps-18-as-lilly-deal-lifts-cash-outlook/
OmniAb Inc. (OABI) shares surged nearly 18% after the company increased its 2026 cash forecast due to new licensing agreements, including one with Eli Lilly for its ion-channel program. This improved outlook provides OmniAb with greater financial stability, reducing immediate dilution risks and enabling continued investment in its antibody discovery technologies. The key challenge for OmniAb remains translating its platform into substantial long-term licensing fees and milestones to maintain its cash position.

Eli Lilly Signs $370 Million Ion Channel Deal With OmniAb, Sending Shares Surging

https://finance.biggo.com/news/12354fd1-1c96-4bba-af0e-eb9569c0841a
Eli Lilly has inked a global collaboration and license agreement with OmniAb for a new ion channel program, a deal potentially worth up to $370 million in milestone payments and tiered royalties. The news sent OmniAb's shares surging in premarket trading. OmniAb also updated its 2026 cash outlook upward due to recent licensing activity.
Advertisement

OABI Reiterates by HC Wainwright & Co. -- Price Target Maintained at $11.00

https://www.gurufocus.com/news/9038925/oabi-reiterates-by-hc-wainwright-co-price-target-maintained-at-1100
HC Wainwright & Co. has reiterated a "Buy" rating for OmniAb (OABI) with a maintained price target of $11.00, signaling confidence despite the stock being currently overvalued at $3.92 against a GF Value™ of $2.92. OmniAb's GF Score™ is 70/100, indicating moderate overall performance with strengths in financial stability and momentum but weaknesses in profitability. Investors are advised to exercise caution due to the overvaluation and the company's unprofitable status.

Lilly taps OmniAb for ion channel discovery in deal worth up to USD 370m

https://allsci.com/news/licensing-and-partnerships/omniab-eli-lilly-deal-secures-usd-370m-milestone/
OmniAb has signed a global collaboration and license agreement with Eli Lilly for an ion channel program, potentially bringing OmniAb up to $370 million in milestone payments and royalties. While OmniAb will handle the discovery phase using its specialized platform for difficult-to-target ion channels, Lilly will retain global rights and manage development and commercialization. This deal expands OmniAb's platform-licensing model, which has already led to approved therapeutics, further solidifying its role as a pure-play discovery platform licensor.

OmniAb, Inc. And Eli Lilly And Company Announce Global Collaboration And License Agreement For Ion Channel Program

https://www.marketscreener.com/news/omniab-inc-and-eli-lilly-and-company-announce-global-collaboration-and-license-agreement-for-ion-c-ce7859dcd089ff23
OmniAb, Inc. has announced a global collaboration and license agreement with Eli Lilly and Company focused on a new ion channel program. This agreement grants OmniAb an upfront payment and eligibility for up to $370 million in research, development, and commercial milestone payments, along with tiered royalties on global net sales. The collaboration leverages OmniAb's technology platform for ion channel discovery and screening.

OmniAb Inc. Stock Pops As Earnings Beat Fuels Guidance Hike

https://www.timothysykes.com/news/omniab-inc-oabi-news-2026_08_17/
OmniAb Inc. (NASDAQ: OABI) saw its stock price surge by 21.6% after reporting a strong Q2 earnings beat, exceeding EPS estimates by $0.08 and nearly tripling revenue expectations. The company also raised its 2026 revenue guidance to $32M–$36M, up from previous estimates, and announced the completion of discovery work on a key collaboration with Veraxa Biotech. This positive news, coupled with a solid balance sheet, positions OABI as a notable momentum play for traders.

OmniAb (OABI) Stock Surges After Big Q2 Earnings Beat

https://stockstotrade.com/news/omniab-inc-oabi-news-2026_08_17-2/
OmniAb (OABI) stock surged over 17% following a significant beat on its Q2 earnings, with EPS exceeding expectations by $0.08 and revenue nearly tripling Wall Street forecasts. The company also raised its FY26 revenue outlook to $32M–$36M and completed discovery work on a bispecific antibody-drug conjugate with Veraxa Biotech, retaining future revenue rights. This performance has positioned OABI as a high-volatility, news-driven stock drawing significant attention from momentum traders.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement